“…Hybrids 37 (IC 50 : 1.61–25.46 μM, MTT assay) with 1,3,4‐thiadiazole backbone at the N‐1 position of isatin moiety showed potential activity against HepG2, AsPc‐1, and HeLa cancer cell lines and the activity was no inferior to that of the reference gefitinib (IC 50 : 5.19–16.41 μM). [ 91 ] Hybrids 38 (IC 50 : 10.46–21.41 μM, MTT assay) with 1,3,4‐thiadiazole backbone at C‐3 position of isatin moiety also showed considerable activity against MCF‐7 cancer cells and the SAR implied that introduction of alkyl or benzyl group into N‐1 position of isatin motif or incorporation of electron‐withdrawing group into phenyl ring (R 2 position) had little impact on the activity. [ 92 ] The isatin–1,3,4‐thiadiazole hybrids 39 were active against a panel of 60 human cancer cell lines derived from nine different cancer types: leukemia, lung, colon, central nervous system (CNS), melanoma, ovarian, renal, prostate, and breast; hybrids 39a,b (IC 50 : 0.65–17.09 μM, MTT assay) possessed broad‐spectrum activity against the tested cancer cell lines.…”